SARS-CoV-2
Variants of Concern Update

This document provides an overview of currently circulating SARS-CoV-2 variants as well as newly identified variants. Characteristics of these variants are monitored and reported including: growth advantage/ transmissibility; disease course/ viral dynamics; clinical features (symptoms and severity); immune evasion, vaccine effectiveness and therapeutics effectiveness; and detection/testing.

All viruses, including SARS-CoV-2, change over time. Most of these changes have little to no impact on the properties of the virus, but some may affect properties such as: how easily it spreads, the associated disease severity, the performance of vaccines, therapeutic medicines, diagnostic tools, or the performance of other public health and social measures.

Nomenclature systems for naming and tracking SARS-CoV-2 genetic lineages have been established by GISAID, Nextstrain and Pango. To assist with public discussions of variants, an expert group convened by WHO recommended using letters of the Greek Alphabet, i.e., Alpha, Beta, Gamma, Delta etc.

A selected sub-set of topic areas are comprehensively updated in each issue of this document. The dates stated for section updates relate to when a comprehensive update was performed, although additional data might have been added in the interim. New information included since the previous update is provided in red text.

This issue has been consolidated and condensed. Out-dated information has been removed as necessary.

Key recent documents

In addition to selected recent pre-prints and published studies, key reports used in this update include:

- WHO: Weekly epidemiological update on COVID-19 - 20 July 2022 (1)
- UKHSA: SARS-CoV-2 variants of concern and variants under investigation in England Technical Briefing 43 – 24 June 2022 (2)
- UKHSA: SARS-CoV-2 variants of concern and variants under investigation in England Technical Briefing 44 – 22 July 2022 (3)
## Contents

**Key recent documents**  
1

**Key new information**  
3

**Overview of variants**  
4

- Omicron lineages: overview of frequency of detection and genetic features 8
- Risk assessment for BA.5 for New Zealand 10
- Characteristics of Omicron 12
- Omicron: Growth advantage/ transmissibility 12
- Omicron: Disease course/ viral dynamics 13
- Omicron: Clinical features (symptoms and severity) 14
- Omicron: vaccine effectiveness 20
- Data from individual studies (Pfizer where available) 20
- Data from reviews (all vaccines) 26
- Vaccine response in T-cells & B cells 28
- Omicron: immune evasion 32
- Omicron: effectiveness of therapeutics 33
- Omicron: Detection 35
- New signals 36
- Delta Overview 37

**Glossary of Terms**  
38

**Abbreviations**  
40

**Useful Links**  
41

**References**  
42
Key new information

- Fewer CoV-2 sequences are being submitted to GISAID than earlier in 2022, and 95% of submitted sequences (globally) between 13th June and 13th July 2022 were the Omicron variant. Among Omicron sequences submitted between 4th and 10th of July, BA.2 represented 3% of sequences, while BA.2.12.1 represented 4.5%, BA.4 represented 11%, and BA.5 represented 54%. This represents a further decrease in proportion that were BA.2 and BA.2.12.1 sequences in the last 3 weeks, and an increase in the proportion of BA.5.(4) The proportion of BA.4 cases has remained stable during this time. (4)
- There is evidence of increased immune evasion of BA.5 compared to BA.2, based on laboratory data. Preliminary data suggest no substantial decrease in vaccine effectiveness, but more data are needed.(2, 5)
- Infection with previous Omicron variants provides protection against subsequent Omicron Infection. Previous Omicron infections is estimated to provide between 76% and 94% protection against symptomatic BA.4/5 infection (time period not reported, but likely within 3 to 5 months since previous infection). (5, 6)
- All RATs available in New Zealand have been screened for acceptable performance. Sensitivity is highly variable between different RATs and is strongly correlated with viral load and symptomatology. In light of the number of mutations in the Spike protein that occurs in Omicron, RATs which target other less mutated antigens such as the ‘N’ or ‘E’ proteins are more likely to maintain high performance of detecting Omicron. There is no strong evidence that there has been a significant decline in the performance of RATs in detecting newer variants of SARS-CoV-2. However, test performance will require ongoing review as new variants arise.
- BA.2.75 is a sub-variant of the BA.2 lineage which has nine new mutations in the spike protein receptors distinguishing it from BA.2.(7) The first two community cases within New Zealand were reported on the 19 July 2022.(8) The World Health Organisation (WHO) has classified BA.2.75 as a variant-of-concern lineage under monitoring on the 7 July 2022.(9) Key opinion leaders state that BA.2.75 may more transmissible than other BA.2 subvariants based on early reports,(10) and that in India this variant is competing (as of mid/late-July) with the most prevalent strain, BA.5.(10)
- BA.5.2.1 is a sub-lineage of Omicron BA.5 that was detected in China on the 8 July 2022.(11) It has not yet been designated a status by the UK or WHO. The first confirmed case of BA5.2.1 was detected in Shanghai (with links to international travel) and cases have since been confirmed across multiple provinces.(11). There is limited evidence around this variant’s properties, such as the transmission potential and disease severity.
Overview of variants

Section updated: 20 July 2022

As of 20 July 2022, Omicron1 was the only circulating Variant of Concern (VoC) as designated by the WHO. (1) There were no currently circulating Variants of Interest as designated by the WHO at that time. Omicron subvariants under monitoring include BA.4, BA.5, BA.2.12.1, BA.2.9.1, BA.2.11, BA.2.13, and BA.2.75. (link)

There is one recently designated variant in the UK (BA.2.75), designated by the UKHSA Variant Technical Group (VTG) on 22 July 2022. Variants detected in the UK over the previous 12 weeks included: (3)

- BA.1 (designated a VoC)
- BA.2 (designated a VoC)
- BA.4 (designated a VoC)
- BA.5 (designated a VoC)
- Omicron (BA.2.12.2)
- Omicron (BA.2.75)
- Delta (B.1.617.2 and sublineages)
- XE Recombinant (BA.1 x BA.2)

Table 1 includes European Centre for Disease Prevention and Control (ECDC) classifications. The ECDC uses the label ‘variant of concern’ when clear evidence is available for a variant indicating a significant impact on transmissibility, severity and/or immunity that is likely to have an impact on the epidemiological situation in the EU/EEA. (12)

Whole genome sequencing efforts are falling globally, potentially obscuring surveillance of VoCs as they emerge and become more prevalent.

The WHO Weekly Epidemiology Update on 20 July 2022 reported that:

’Several subvariants of Omicron have emerged and some of these are being monitored by WHO. BA.2.75 is an Omicron subvariant under monitoring, with earliest sequences reported from May 2022. BA.2.75 has nine additional mutations in the spike compared to BA.2. There is no evidence yet of the extent to which these mutations impact on transmissibility and disease severity compared to other circulating lineages. As of 18 July, 250 sequences of BA.2.75 from 15 countries have been reported on GISAID.’ (1)

---

1 Includes BA.1, BA.2, BA.3, BA.4, BA.5 and descendent lineages. It also includes BA.1/BA.2 circulating recombinant forms such as XE.
Table 1: Overview of SARS-CoV-2 variants of public health interest

Table updated: 22 July 2022

<table>
<thead>
<tr>
<th>Pango lineage</th>
<th>WHO label</th>
<th>UKHSA label</th>
<th>UKHSA designation</th>
<th>ECDC designation</th>
<th>Earliest documented samples</th>
<th>Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA.2.75</td>
<td>Omicron sub-lineage BA.2.75</td>
<td>V-22JUL-01</td>
<td>Variant</td>
<td>Variant of Interest as of 07 July 2022 (13)</td>
<td>India, 02 June 2022</td>
<td>Detected in GISAID in the past 12 weeks across 15 different countries including the UK. (1)</td>
</tr>
<tr>
<td>B.1.1.529/ BA.4</td>
<td>Omicron sub-lineage BA.4</td>
<td>V-22APR-03</td>
<td>Variant</td>
<td>Variant of Concern as of 12 May 2022 (previously variant of interest) (14)</td>
<td>South Africa, January 2022. (15)</td>
<td>Detected in the UK in the past 12 weeks as at 22 July. (3, 16) Dominant in South Africa along with BA.5. (14)</td>
</tr>
<tr>
<td>B.1.1.529/ BA.5</td>
<td>Omicron sub-lineage BA.5</td>
<td>V-22APR-04</td>
<td>Variant</td>
<td>Variant of Concern as of 12 May 2022 (previously variant of interest) (14)</td>
<td>South Africa, February 2022. (15)</td>
<td>Dominant globally. (1)</td>
</tr>
<tr>
<td>BA.2.12.1</td>
<td></td>
<td></td>
<td>Signal in monitoring</td>
<td></td>
<td></td>
<td>Detected in the UK in the past 12 weeks as at 22 July. (3)</td>
</tr>
<tr>
<td>B.1.1.529/BA.2</td>
<td>Omicron</td>
<td>VOC-22JAN-01</td>
<td>Variant of concern (previously a variant under investigation)</td>
<td>Variant of Concern (12)</td>
<td></td>
<td>Detected in the UK in the past 12 weeks as at 22 July. (3)</td>
</tr>
<tr>
<td>BA.3</td>
<td></td>
<td></td>
<td>Signal in monitoring (previously Variant in monitoring)</td>
<td>Variant under monitoring (12)</td>
<td>South Africa (12)</td>
<td>Detected in the UK in the past 12 weeks as at 22 July. (3)</td>
</tr>
<tr>
<td>B.1.1.529/BA.1</td>
<td>Omicron</td>
<td>VOC-21NOV-01</td>
<td>Variant of concern</td>
<td>Variant(12)</td>
<td></td>
<td>Detected in the UK in the past 12 weeks as at 22 July. (3)</td>
</tr>
<tr>
<td>Delta and Omicron recombinant lineages (UK)</td>
<td></td>
<td></td>
<td>Signal in monitoring (previously Variant in monitoring)</td>
<td></td>
<td>United Kingdom, Feb-2022 (17, 18)</td>
<td>Detected in the UK in the past 12 weeks as at 22 July. (3)</td>
</tr>
<tr>
<td>AY.119.2/BA.1.1 Recombinant</td>
<td></td>
<td></td>
<td>Signal under monitoring</td>
<td></td>
<td></td>
<td>Not detected in the UK in the past 12 weeks as at 22 July. (3)</td>
</tr>
<tr>
<td>Pango lineage</td>
<td>WHO label</td>
<td>UKHSA label</td>
<td>UKHSA designation</td>
<td>ECDC designation</td>
<td>Earliest documented samples</td>
<td>Distribution</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>XD Recombinant (Delta x BA.1)</td>
<td>V-22APR-01</td>
<td>Variant (previously signal under monitoring)</td>
<td></td>
<td>France, Jan-2022 (9)</td>
<td>Not detected in the UK in the past 12 weeks as at 22 July.(3)</td>
<td></td>
</tr>
<tr>
<td>XE Recombinant (BA.1 x BA.2)</td>
<td>V-22APR-02</td>
<td>Variant</td>
<td></td>
<td>First case detected on 19 January 2022. (17, 18)</td>
<td>Detected in the UK in the past 12 weeks as at 22 July.(3)</td>
<td></td>
</tr>
<tr>
<td>AY.119.2/BA.1.1 Recombinant</td>
<td></td>
<td>Signal under monitoring</td>
<td></td>
<td></td>
<td>Not detected in the UK in the past 12 weeks as at 22 July.(3)</td>
<td></td>
</tr>
<tr>
<td>BA.1/BA.2 Recombinant (with unique mutation C3583T)</td>
<td></td>
<td>Signal in monitoring</td>
<td></td>
<td></td>
<td>Detected in the UK in the past 12 weeks as at 22 July.(3)</td>
<td></td>
</tr>
<tr>
<td>XF Recombinant</td>
<td></td>
<td>Signal in monitoring</td>
<td></td>
<td></td>
<td>Not detected in the UK in the past 12 weeks as at 22 July.(3)</td>
<td></td>
</tr>
<tr>
<td>B.1.617.2 and sub-lineages</td>
<td>Delta</td>
<td>V-21APR-02 (previously VOC-21APR-02)</td>
<td>Variant (previously a variant of concern)</td>
<td>Variant of Concern (12)</td>
<td>India, Oct-2020 (9)</td>
<td>Detected in the UK in the past 12 weeks as at 22 July.(3)</td>
</tr>
<tr>
<td>B.1.1.7</td>
<td>Alpha</td>
<td>V-20DEC-01 (previously VOC-20DEC-01)</td>
<td>Variant (previously a variant of concern)</td>
<td>De-escalated variant</td>
<td>United Kingdom, Sep-2020 (9)</td>
<td>Detected in GISAID, but not in the UK, in the past 12 weeks as at 22 July.(3)</td>
</tr>
<tr>
<td>B.1.351</td>
<td>Beta</td>
<td>V-20DEC-02</td>
<td>Variant of Concern (last report unclear designation)</td>
<td></td>
<td>South Africa, May-2020 (9)</td>
<td>Not detected in the UK in the past 12 weeks as at 22 July.(3)</td>
</tr>
<tr>
<td>AY.4.2</td>
<td></td>
<td>V-21OCT-01 (previously VUI-21OCT-01)</td>
<td>Variant (previously a variant under investigation) - AY.4.2 is a sub-lineage within Delta that has been assigned as a distinct variant by UKHSA.</td>
<td>De-escalated but monitored under Delta VOC</td>
<td></td>
<td>Detected in the UK in the past 12 weeks as at 22 July.(3)</td>
</tr>
<tr>
<td>B.1.640</td>
<td></td>
<td></td>
<td>Signal in monitoring (previously Variant in monitoring)</td>
<td></td>
<td>Multiple countries, Sep-2021 (9)</td>
<td>Not detected in the UK in the past 12 weeks as at 22 July.(3)</td>
</tr>
<tr>
<td>B.1.617.3</td>
<td>V-21APR-03</td>
<td>Variant</td>
<td></td>
<td></td>
<td></td>
<td>Not detected in the UK in the past 12 weeks as at 22 July.(3)</td>
</tr>
<tr>
<td>Pango lineage</td>
<td>WHO label</td>
<td>UKHSA label</td>
<td>UKHSA designation</td>
<td>ECDC designation</td>
<td>Earliest documented samples</td>
<td>Distribution</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>B.1.621</td>
<td>Mu</td>
<td>V-21JUL-01 (previously VUI-21JUL-01)</td>
<td>Variant (previously Variant under Investigation)</td>
<td>Colombia, Jan-2021 (9)</td>
<td>Not detected in the UK in the past 12 weeks as at 22 July. (3)</td>
<td></td>
</tr>
<tr>
<td>P.1</td>
<td></td>
<td>Removed from UKHSA list</td>
<td>Removed from UKHSA list</td>
<td>Brazil, Nov-2020 (9)</td>
<td>Not detected in the UK in the past 12 weeks as at 22 July. (3)</td>
<td></td>
</tr>
</tbody>
</table>
Omicron lineages: overview of frequency of detection and genetic features

Section updated: 20 July 2022

- Omicron was first detected in November 2021 causing a rapid resurgence of COVID-19 cases in South Africa. The WHO designated it as the fifth variant of concern of SARS-CoV-2 (Omicron, B.1.1.529).
- The Omicron variant is dominant across the world, displacing the Delta variant. Spread was rapid even in regions with high levels of population immunity.
- Compared to the Alpha, Beta, Gamma, and Delta VoCs, the Omicron variant has the greatest number of mutations; 50 mutations accumulated throughout the genome. At least 32 of these mutations are in the spike protein (twice as many as Delta) enabling highly efficient evasion from neutralising antibodies.
- Omicron has continued to evolve, leading to further variants with slightly different genetic constellations of mutations.
- The Omicron variant (B.1.1.529) comprises a number of lineages and sub-lineages.
- Major descendant lineages include BA.1, BA.2, BA.3, BA.4, BA.5
- BA.2 and BA.3 are evolutionarily linked to BA.1 and BA.4 and BA.5 are evolutionarily linked to BA.2.
- Recombinant lineages include XE, a BA.1/BA.2 recombinant
- There are a large number of mutations differentiating Omicron variants from other known SARS-CoV-2 lineages.
- BA.1 and BA.2
  - In December 2021, Pango announced designation of two genetically distinct sub-lineages of B.1.1.529 as BA.1 (B.1.1.529.1) and BA.2 (B.1.1.529.2). BA.1 for the original globally distributed lineage, and BA.2 for the new outlier lineage. The prefix BA was then an alias for B.1.1.529.
  - BA.2 was designated a variant under investigation (VUI) by UKHSA on 21 January 2022. BA.2 contains 29 mutations in the spike protein and a deletion at 25-27. Some of the mutations in the spike protein are shared with BA.1.
  - Differentiation of BA.1 from BA.2 requires whole genome sequencing (WGS). BA.1 contains the spike deletion at position 69-70 which is associated with S-gene target failure (SGTF) in some widely used PCR tests.
  - SGTF patterns have been used to assess the spread of Omicron lineage BA.1.
  - The BA.2 genome generally is S-gene target positive, but as of 30 March 2022, the UKHSA reported that 0.16% of BA.2 samples sequenced had the deletion at position 69-70.
  - UKHSA is no longer reporting SGTF patterns. UK testing policy on 1 April resulted in a substantial reduction in tests processed through assays which can report SGTF. SGTF is
no longer a reliable representation of variants in the population, and the UKHSA will not be reporting it going forward.(16)

- **BA.3**
  - BA.3 has the SGTF deletion (Δ69-70) so can be detected using PCR tests that detect SGTF, and has a combination of mutations found in BA.1 and BA.2 spike proteins.(27)
  - As of 01 June 2022, the proportion of sequences submitted to GISAID that were BA.3 in the past 30 days, has declined to <1%. (28)

- **BA.4 and BA.5**
  - These were classified by the VTG on 6 April 2022 as V-22APR-03 and V-22APR-04, respectively.(29) WHO announced that BA.4 and BA.5 had been added to their list of variants for monitoring on 12 April 2022. The ECDC classified both as variants of concern on 12 May.(14)
  - BA.4 and BA.5 have many mutations in common with the BA.2 variant,(15) as well as a number of additional mutations. The BA.4 and BA.5 sub-variants tend to be discussed together because the mutations in their spike protein gene are identical (but differ in mutations elsewhere in the genome).(15)
  - Among Omicron sequences submitted to GISAID between 4th and 10th of July, BA.4 represented 11% of sequences, and BA.5 represented 54%. (1) This is an increase in the proportion of BA.5 while the proportion of BA.4 has remained stable or slightly declined in the last month. (1)
  - At 22 July 2022, BA.5 is the dominant variant in the UK, with 79% of cases sequenced identified as BA.5 and BA.4 making up just 17%. (3) An updated growth model suggests that the relative growth rate of BA.2.12.1 and BA.4 are both in decline. The relative growth rate of BA.5 has slowed considerably, but its representation is likely still increasing. It is likely that the slowing in BA.5 is due both to it saturating as the dominant variant (relative growth will always eventually saturate) and misclassification of BA.5 sequences as ‘other’. (3)

- **BA.2.12.1**
  - Among Omicron sequences submitted to GISAID between 4th and 10th of July, BA.2.12.1 represented 4.5% of cases. This represents a further decrease in proportion that were BA.2.12.1 sequences in the last 3 weeks.(1)
## Risk assessment for BA.5 for New Zealand

*Section updated: 22 July 2022*

### Table 2: Risk assessment for BA.5 for New Zealand

<table>
<thead>
<tr>
<th>Overall growth advantage</th>
<th>Overall Risk Assessment*</th>
<th>Confidence level</th>
<th>Assessment and rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High</td>
<td>High</td>
<td>Evidence of a growth advantage compared to BA.2.</td>
</tr>
</tbody>
</table>

As of 15 July BA.5 is the predominant variant in New Zealand, with a growth advantage over the previously dominant variant BA.2. The growth in BA.5 observed in the whole genome sequencing of individual testing is consistent with the growth observed in wastewater. There was an associated overall increase in coronavirus (COVID-19) cases. As cases of BA.5 were increasing and displacing BA.2 in May and early June, the estimated growth rate of BA.5 for New Zealand was approximately 9% per day or 7 day doubling time. (30) This is consistent with growth advantages observed internationally.

<table>
<thead>
<tr>
<th>Growth advantage 1: Transmissibility</th>
<th>Insufficient data</th>
<th>Insufficient data</th>
<th>Evidence of increased immune evasion compared to BA.2, based on laboratory data; however, preliminary data suggest no substantial decrease in vaccine effectiveness, but this is subject to revision. Growth advantage is likely mostly due to immune evasion properties, rather than changes to intrinsic transmissibility.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory data: BA.5 demonstrates a moderate drop in neutralising antibodies compared to other Omicron variants BA.1 and BA.2, and protection conferred from vaccination with 3 doses. Less of an impact was observed for samples associated with ‘hybrid’ protection, e.g., by ‘breakthrough’ infections after vaccination. (32-34)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reinfection: There is limited evidence on the rates of reinfection in New Zealand or internationally, including after prior Omicron variant infection. Prior infection with BA.1 or BA.2 provides some protection against BA.5; prior infection with non-Omicron variants is lower. (5, 6, 35)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The overall risk assessment is presented in comparison to the prior or current predominant variant (BA.2). ‘High’ indicates the assessed variant as worse than BA.2 in a characteristic, ‘medium’ equivalent, ‘low’ improved. The confidence level in the available data available is also assessed.*
Vaccine effectiveness (VE): There is insufficient data for a robust assessment of vaccine effectiveness but in population and survey data there were no early indicators of a large change in VE against symptomatic infection from BA.2 to BA.5. The current epidemiological data, whilst incomplete, is consistent with the neutralisation findings.

<table>
<thead>
<tr>
<th>Severity</th>
<th>Medium</th>
<th>Low</th>
<th>In vitro data suggests realised severity is similar to previous Omicron variants; epidemiological data requires close monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>There has been an increase in people admitted to hospital with COVID-19 in Aotearoa. There is still limited data on the severity of BA.5.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>To date, countries which have experienced BA.5 waves have not experienced apparent high severity of disease and hospitalisation rates have tended to remain lower than previous waves. (12, 36, 37) One study suggests greater risk of hospitalisation compared to BA.2 after adjusting for age.(5)</td>
</tr>
</tbody>
</table>

Table 3 Risk assessment for BA.5 variant of SARS-CoV-2, 04 July 2022. Assessment based on UKHSA risk assessment for BA.4 and BA.5 (VOC-03-APR2022 and VOC-04-APR2022) from 22 June 2022.(37) Data updated for the context of Aotearoa New Zealand. The risk assessment is revised as new data emerges.
Characteristics of Omicron

Omicron: Growth advantage/ transmissibility

Section updated: 16 May 2022

Omicron is more transmissible and has a higher secondary attack rate than Delta

- A study estimated that Omicron had a growth advantage that corresponds to a 5.4-fold (95% CI = 3.1–10.1) weekly increase in cases compared with Delta. (19)
- Data from Denmark (to 18th Dec 2021), the effective reproduction number of Omicron is 3.19 (95%CI 2.82–3.61) times greater than Delta under the same epidemiological conditions. (38)
- Data from Texas, USA, indicated a case-doubling time for Omicron of 1.8 days, three times faster than for Delta in this area. (39)
  - Omicron is more associated with asymptomatic infection and transmission than Beta and Delta. (40)
  - Contact tracing data show a greater proportion of transmission happening outside the household for Omicron than for Delta. (41)
- Data from the UK estimated a shorter generation time (interval between infection events) for Omicron with a mean of 1.5–3.2 days (standard deviation [SD] 1.3–4.6 days), compared to a mean of 2.5–4 days (SD 1.9–3 days) for Delta. (14)
- UKHSA analysis of contact-tracing data shows the mean serial interval for BA.1 is 3.72 days (95% CI: 3.62 - 3.80). (42)

Household transmission

- Secondary Attack Rate (SAR) of 29% for BA.1 compared with an SAR of 39% for BA.2 across households infected with Omicron. (43)
- SAR for Omicron ranges from 7.6% to 50% depending on country and setting. (41, 44, 45)

Other data

- The Omicron variant has a survival time in the environment of 21.1 hours (95% CI: 15.8–27.6) compared to 16.8 hours (95% CI: 13.1–21.1) for Delta. (46) The high environmental stability of Omicron could increase the risk of contact transmission and contribute to its spread. However, convincing evidence of fomite transmission has not been demonstrated for any variant to date.
- A study found that initial testing of HCWs if they had a household positive case in majority of instances, was sufficient to prevent nosocomial transmission to patients. (47)
- A human challenge study using wild-type virus found that a dosage of 10 TCID50 (very low dose) was sufficient to result in an infection. Also, they found that viral shedding occurs in both the nose and throat at high levels irrespective of symptom severity. (48)
Omicron: Disease course/ viral dynamics

Section updated: 16 May 2022

Median or mean incubation period 3-4 days, maximum incubation unclear (6-8 days reported). Omicron may have a shorter serial interval than Delta.

NOTE: Incubation period refers to the time from infection until symptom development. The serial interval refers to the time from illness onset in the primary case to illness onset in the secondary case. The latent period refers to the time from infection until the person becomes infectious (and more likely to test positive)

Incubation period

Single exposure event data (assumes participants infected at event):

- Incubation periods are short, ranging from 0 to 8 days, with a mean or median incubation period of around 3 days (49-52)

Human challenge studies (non-Omicron, novel transmission data)

- Incubation period of 2 to 4 days after inoculation with wild-type virus. (48) Viral load (VL) rose steeply and peaked around day 4-5.

Serial Interval

- The mean serial interval ranges from 2.5 to 4.8 days. (44, 52-54)

Latent period:

Human challenge studies (non-omicron, novel transmission data)

- Viral shedding by qPCR became quantifiable in throat swabs from 40 hours post-inoculation, significantly earlier than in the nose, where initial viral quantifiable detection occurred at 58 hours post-inoculation. (48)

Duration of infectiousness

- Studies for several countries (Japan, Switzerland, Singapore) among predominately vaccinated people show that for vaccinated people viral RNA from Omicron samples was highest 3-6 days after diagnosis or symptom onset and then decreased gradually, with a marked decrease 8-10 days after diagnosis or symptom onset. (55-57)

Duration of illness

- Time to resolution of symptoms varies, and at the end of follow-up, five individuals still reported symptoms, while the rest (16 individuals) reported symptoms lasting 1 to 9 days. (49)

- One study found positive viral cultures obtained from day 2 of infection but were cleared and negative by day 5 of illness. (56)
Hospitalisation

Hospitalisation frequency for Omicron relative to Delta

Adjusted for vaccination status (important for understanding basic differences in severity as it can remove differences in vaccine effectiveness from assessment, though residual confounding for vaccination status may still occur):

- Risk of hospitalisation/severe disease was found to be lower for Omicron than Delta in multiple countries (Sweden, Norway, the US, France, Scotland\(^2\), the UK, Canada\(^3\), Portugal), with estimates ranging from 40-73%. (58-68)

- A study from South Africa showed that much of the severity reduction observed for Omicron relative to Delta was due to prior infection and vaccination. Intrinsically reduced virulence accounted for a ~25% reduced risk of hospitalisation/death compared to Delta. (69)

- However, a US study found a relative increase in emergency department visits (86%) and hospitalisations (76%) from Omicron compared to the Delta period, though this was due to the higher volume of cases and there was a relative decease in the length of stay in hospitals (-27%). (70)

- Danish data (71) stratified rather than adjusted by vaccination status:
  - Among those with <2 doses: 43% lower risk of hospitalisation
  - Among those with 2 doses: 29% lower risk of hospitalisation
  - Among those with 3 doses: 50% lower risk of hospitalisation

- Unadjusted for vaccination status (provides indication of burden on healthcare at the level of vaccination in country where study conducted):
  - Reduction in hospitalisation of 38% for emergency department attendance or admission, and 62% for admission (41)
  - Reductions in hospitalisation compared to Delta range from 36% to 53% depending on country. (71-73)

Hospitalisation frequency (not compared to Delta)

Hospitalisation frequency varies depending on country/region but ranges from 0.25% in (63)Canada to 3.6% in (74)India, with many countries reporting values between these two values. (72, 75)

Paediatric hospitalisation

- Both the UK and South Africa saw a rapid increases in paediatric COVID-19 cases and hospitalisations in late 2021, mirroring high community transmission of the Omicron variant, with the UK seeing a 3-fold increase in 2 weeks. (76, 77)

\(^2\) adjusted for age, sex, socioeconomic status, vaccination status and clinical risk factors.
\(^3\) adjusted for vaccination status and region
• In the UK, the most rapid rise was among children under 5 years, however some small reviews of Omicron admissions in infants found those admitted were not severely unwell, and less severe than previous waves. (77-79)

• A US study of children under 5 years found a significantly lower risk for severe clinical outcomes in the 3-day time-window following initial Omicron infection compared to Delta. (80) Risk for an ED visit was 18.83% (vs 26.67%), hospitalisation was 1.04% (vs 3.14%), ICU admissions was 0.14% (vs 0.43%), and mechanical ventilation was 0.33% (vs 1.15%).

• Another US study found during the Omicron wave, paediatric acute upper airway infections have increased with more developing severe disease, suggesting Omicron replicates more efficiently in the conducting airways. (81)

Risk factors for hospitalisation with Omicron

• A UK study found the age range of individuals admitted with Omicron to 29 December 2021 was 0 to 100 years (median: 45.5 years); 496 (60.9%) were aged 40 years or more; 30.8% were aged 70 years or more. (64)

• Public Health Scotland data reported on hospital admissions for COVID-19 (week of 22-28 December 2021) shows approximately 44% were in people 60 plus years of age, and 21% of admissions were in people aged 80 plus. (82)
  o Most cases of COVID-19 at this time in Scotland were Omicron but the proportion of cases of the Omicron variant for each age-group hospitalised are not reported.

Time to hospitalisation with Omicron

Currently, there is no studies to date that have investigated this.

Time in hospital with Omicron

• Hospital stays from Omicron infection range from 1 to 6 days and this varies depending on country and demographic but the mean time in hospital tends to be 3 to 4 days. (39, 72, 83)
  Overall, hospital stays for Omicron infections are significantly shorter compared to that of Delta infections. (65, 66, 84)

ICU admission

Severe/ICU/ventilated frequency

• ICU admission from Omicron infection is around 70-74% lower than from Delta infection. (65, 72)

• South African data: Among hospitalised individuals, after controlling for factors associated with severe disease⁴, the odds of severe disease did not differ between S-Gene Target-Failure (SGTF, interpreted as Omicron) infected individuals compared to non-SGTF individuals diagnosed during the same time period (aOR 0.7, 95% CI 0.3-1.4).(85) Compared to earlier

---

⁴ controlled for factors known to be associated with severity (age, presence of comorbidity, sex, province and healthcare sector) and adjusted for the number of days between the date of specimen collection and date of hospital admission, known prior SARS-CoV-2 infection and SARS-CoV-2 vaccination status.
Delta infections, after controlling for factors associated with severe disease⁵, SGTF-infected individuals had lower odds of severe disease (aOR 0.3, 95% CI 0.2-0.5).

- The risk of needing ventilatory support among patients with Omicron infection is significantly lower than for Delta, (39, 72, 83)

**Death**

**Death frequency relative to Delta**

Studies have found a reduction in death relative to Delta, but the extent of the reduction was influenced by a range of factors.

In South Africa, the reduction in death was 73%, however when prior infections and vaccination were also considered this impact was lower (HR: 0.72, a 28% reduction relative to Delta).(69) The odds of death in a Portugal study were 0.14 (95% CI: 0.0011-1.12), representing a reduction in the risk of death of 86% for Omicron compared with Delta.(66)

US: Unadjusted hazard ratios for mortality associated with Omicron variant infection was 0.09 (95% CI: 0.01-0.75)(72) but unadjusted ratios could be confounded by many factors, and the short follow up time might bias results.

UK data in long term care facility residents: Reduced risk of death within 28 days of a new diagnosis in the Omicron dominant period (1.1 deaths / 1000 person-days, 95% CI: 0.6-2.2) compared to the pre-Omicron period (3.8 deaths / 1000 person-days, 95% CI: 2.8-5.2).(67)

**Time to death**

UK data: median time from Omicron specimen date to death was 5 days (range 0 to 14).(64) Note that specimen date might not reflect date of symptom onset.

---

⁵ Controlled for factors known to be associated with disease severity (age, presence of co-morbidity, sex, province and healthcare sector), and adjusted for number of days between date of specimen collection and date of hospital admission, known prior SARS-CoV-2 infection and SARS-CoV-2 vaccination status.
Symptomatology

Symptoms may be milder in previously infected and/or vaccinated individuals. Recent UK data suggests a substantial proportion of Omicron cases may be asymptomatic – estimates range from 25-54%. The most common symptoms reported are sore throat, cough, runny/stuffy nose, and fatigue. Additional data supports earlier reports that loss of smell and taste is less commonly reported by Omicron cases than for Delta, and that sore throat is more commonly reported.

- The most common symptoms reported in early data were: cough; runny/stuffy nose; and fatigue.(50, 86-88)
- The COVID Symptoms Study reports that headache and sneezing are also common symptoms of Omicron infection. (89)
- Data suggests no difference in symptoms between vaccinated and unvaccinated cases of COVID-19 infection but milder and of shorter duration in vaccinated cases (data likely to include both Omicron and Delta cases). (link)
- A study from Canada of 1,063 cases of Omicron (confirmed or suspected) found that only 10% reported shortness of breath.(88)
- Symptoms reported in paediatric cases in South Africa have included fever, vomiting, diarrhoea and convulsions.(76)
- UKHSA comparison of Omicron to Delta symptoms from confirmed Omicron cases and confirmed Delta cases in the period between 01 December to 28 December 2021.
  o Omicron cases were less likely to report loss of smell and taste compared to Delta cases (13% of Omicron cases compared to 34% of Delta cases).
  o However, Omicron cases were more likely to report a sore throat than Delta cases (53% of Omicron cases, 34% of Delta cases).
  o Adjustments were made for age group, sex, ethnicity, self-reported vaccination status (two or more doses, one or no dose, or missing data), geographical region of residence, and the week in which symptoms began.
  o UKHSA states that the findings relating to reports of sore throat could be incidental and suggests that sore throat may not be a specific predictor of Omicron infection, as another recent study led by Oxford University and the Office for National Statistics (90) found increased reports of sore throat in both PCR-positives and symptomatic PCR-negative cases. More data are required to understand which symptoms may be used to identify Omicron infections.
- A study from Korea investigated the clinical and epidemiological characteristics of 40 patients with Omicron (42.5% were fully vaccinated) and found that half of the patients (19, 47.5%) were asymptomatic, while the others had mild symptoms.(91)
  o The most common symptoms were sore throat (25%), fever (20%), headache (15%), cough (12.5%), and sputum production (12.5%).
  o While these findings are consistent with recent reports of mild symptoms from other sources, given the small size and low median age of the study (39.5), more data are required to understand symptoms and determine the severity of Omicron.
• A Singapore study compared symptoms between Omicron and Delta found having sore throat was significantly more common in Omicron patients (sore throat 46.0 vs 23.0%, p=0.005) and less likely to develop pneumonia (3.4 vs 16.1%, p=0.005).
  o Median neutrophil count, C-reactive protein and lactate dehydrogenase levels were lower in Omicron infections.
  o Patients with booster vaccination were significantly older and had higher anti-spike antibody but were similar in clinical and laboratory features including median initial and lowest PCR cycle threshold values.(56)
• A study from Jordan showed that the most frequent symptoms for Omicron were fever, cough, sore throat, runny nose, joint and muscle pain, and general fatigue. Loss of taste and smell was only reported in 1.2% of patients.(92)
• UK data reported from the Real-time Assessment of Community Transmission-1 (REACT-1) survey (Round 17; 99% Omicron cases) found a substantial proportion (approximately 25%) of positive tests were in asymptomatic people.(93)
  o Vaccine status of individuals within this group was not included in the report.
• Data from the UK COVID-19 Infection Survey found fewer people reported symptoms within 35 days following the first observed positive test from reinfection than in their initial infection episode, suggesting reinfections are more likely to be asymptomatic, (noting that these symptoms are self reported). (94)
  o Viral load, indicated by Ct Value, was on average lower in reinfections (Ct value of 25.15) than initial infections (Ct Value of 26.91), in data collected from 20 December 2021 onwards.
  o There has been a further reduction in reports of loss of taste/smell, previous present 16% of cases in November dropping to 11-12% of cases with a string positive.
  o The UK COVID-19 Infection Survey collects data on characteristics of people testing positive for COVID-19, including data on symptoms for those who had strong positive tests - Ct value under 30 (see imbedded table below). These data are provisional, reflect infections reported in the community, and exclude infections reported in hospitals, care homes, or other institutional settings.
  o While the December data provide an indication of the common symptoms of the Omicron variant, Omicron was not dominant for the whole of December, so these data are not a complete representation and further information is required. Data from the UK COVID-19 Infection Survey which reported on what can be considered the beginning of the ‘Omicron period’ (20 December 2021 23 January 2022) indicates that approximately 54% of participants did not report any symptoms (within 35 days after first observed positive test), considered asymptomatic.(95)
### Percentages of People with Symptoms

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Percentage of People with this symptom within 35 days of a positive PCR, among those people with a Ct value under 30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>January 2022</td>
</tr>
<tr>
<td>Any symptoms</td>
<td>61.27</td>
</tr>
<tr>
<td>No symptoms (asymptomatic)</td>
<td>38.73</td>
</tr>
<tr>
<td>Classic symptoms (cough, fever, shortness of breath, loss of taste, loss of smell)</td>
<td>49.46</td>
</tr>
<tr>
<td>Loss of taste or smell</td>
<td>11.1</td>
</tr>
<tr>
<td>Gastrointestinal symptoms (abdominal pain, nausea or vomiting, diarrhoea)</td>
<td>14.46</td>
</tr>
<tr>
<td>Cough</td>
<td>40.49</td>
</tr>
<tr>
<td>Fatigue (weakness)</td>
<td>34.13</td>
</tr>
<tr>
<td>Headache</td>
<td>36.63</td>
</tr>
<tr>
<td>Sore throat</td>
<td>35.71</td>
</tr>
<tr>
<td>Fever</td>
<td>21.12</td>
</tr>
<tr>
<td>Loss of smell</td>
<td>7.58</td>
</tr>
<tr>
<td>Muscle ache (myalgia)</td>
<td>23.25</td>
</tr>
<tr>
<td>Loss of taste</td>
<td>9.14</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>11.53</td>
</tr>
<tr>
<td>Nausea or vomiting</td>
<td>8.19</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>6.23</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>5.46</td>
</tr>
</tbody>
</table>

The above table is taken from the 22 June 2022 edition of UK COVID-19 Infection Survey. (94)

### BA.2-specific clinical features (symptoms and severity) information

**Preliminary analyses show no differences in frequency of hospitalisation for BA.2 compared to BA.1.**

- Multiple studies have failed to show a difference in frequency of hospitalisations or severity between BA.1 and BA.2. (96-99)

- Data on Omicron in children suggested that symptoms were less severe than previous variants, and paediatric deaths were rare. However, these data were from populations in which a majority were already protected from past infection, vaccination or both. (100)

- A large study of an uninfected and unvaccinated population of children investigated severe outcomes among 1,147 children aged 11 years or below who were hospitalised between 5 February and 28 February 2022 (a BA.2-dominant period). Intrinsic severity of BA.2 in children who had no past COVID-19 or vaccination was determined to be not mild. (100)
  - Children hospitalised during the BA.2 dominant period had higher odds of PICU admissions, mechanical ventilation and oxygen use.
  - BA.2 was reported to be more neuropathogenic than previous SARS-CoV-2 variants, influenza and parainfluenza viruses, resulting in more seizures.
Omicron: vaccine effectiveness

Section updated: 16 May 2022

Vaccine effectiveness (VE)

Data described below relate to the original “wild type” vaccines (not an Omicron-based vaccine).

2 doses of Pfizer (primary course): VE against infection with Omicron is approximately 50% soon after 2 doses of Pfizer. Within 5-6 months of the second dose VE wanes to levels unlikely to reduce transmission and the initial VE against hospitalisation of around 60-70% after a primary vaccine course declines to ~45%.

Booster dose: VE against infection with Omicron is around 55-70% after a booster dose of Pfizer, but also wanes. VE against hospitalisation increases to ~90% after a Pfizer booster dose (including in those over 65 years of age) and remains at above 70% 3 months after the booster. Duration of effectiveness of Pfizer vaccine against hospitalisation after a booster dose has not been fully established, but effects remain higher for longer than for protection against infection.

Data about clinical effectiveness against BA.5 remain limited. (2, 5) Immunological data about vaccine induced BA.5 neutralising antibody will be reported in section “Vaccine response in T-cells & B cells”, below, until clinical data are available.

(Note: Pfizer and BioNTech have begun enrolment for a clinical trial to test the safety, tolerability, and immunogenicity of an Omicron-based vaccine candidate in 1,420 healthy adults aged 18-55 years. (link) Pfizer is hoping to be able to deliver the vaccine in (southern hemisphere) Spring 2022. However, testing in primates has shown no advantage of an Omicron specific mRNA (Moderna) booster over a booster with the regular Moderna vaccine (link)).

Data from individual studies (Pfizer where available)

VE against infection, symptomatic infection and onward transmission

Summary of the international data:

- VE against infection with Omicron is 40-55% soon after 2 doses of Pfizer. This represents an epidemiologically important reduction in transmission.
- VE against infection with Omicron wanes to levels unlikely to reduce transmission within 5-6 months of the second dose.
- VE against infection with Omicron is around 55-69% after a booster dose of Pfizer. Although there is some indication of waning after a booster dose, data about symptomatic infection in the UK suggests this occurs more slowly after a booster dose than after a primary course of Pfizer, with VE against symptomatic infection remaining above 50% in those that had received a booster more than 10 weeks prior.

Data about onward transmission are scarce and are only available for “all vaccines” and not Pfizer alone. Non-peer-reviewed data from a small study suggest that vaccinated people infect fewer people in their household (a setting where many “exposure events” are likely to occur, generally resulting in lower “vaccine efficacy” than in settings with less intense contact.)
### Table 4: Vaccine effectiveness on transmission related parameters (Omicron)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Outcome</th>
<th>2 doses (95% CI in brackets)</th>
<th>3 doses (95% CI in brackets)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Soon after</td>
<td>Later effect</td>
<td>Data not reported by time since 2nd dose</td>
</tr>
<tr>
<td>Pfizer (all doses)</td>
<td>Infection</td>
<td>Denmark (101)*:</td>
<td>91-150 days</td>
<td>-76% (-95 - -60)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1-30 days</td>
<td>55% (24- 74%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>31-60 days</td>
<td>16% (-21 – 42%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>61-90 days</td>
<td>10% (-10 – 26%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Denmark (102)</td>
<td>&gt;120 days</td>
<td>13% (13-14%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Portugal(103)*:</td>
<td>28% (12-41%)†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symptomatic infection**</td>
<td>UKHSA (77):</td>
<td>70-98d¥</td>
<td>29% (27-30%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14-28d¥</td>
<td>&gt;180d¥</td>
<td>14% (12-16%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64% (62-66%)</td>
<td>68% (66-70%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>UKHSA (77):</td>
<td>&gt;70d ¥</td>
<td>54% (52-56%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USA (104):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine (Moderna, or Moderna and Pfizer)</td>
<td>Infection</td>
<td>Onward transmission</td>
<td>2 doses (95% CI in brackets)</td>
<td>3 doses (95% CI in brackets)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td></td>
<td>USA (106):</td>
<td>USA (106):</td>
<td>USA (106):</td>
<td>USA (106):</td>
</tr>
<tr>
<td></td>
<td>14-90 days</td>
<td>91-180 days</td>
<td>14% (11 – 17%)</td>
<td>14-60 days</td>
</tr>
<tr>
<td></td>
<td>44% (35-52%)</td>
<td>24% (16-30%)</td>
<td>72% (70-73%)</td>
<td>70% (68% - 79%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>181-270 days</td>
<td>14% (10-17%)</td>
<td>47% (41- 54%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;270 days</td>
<td>&gt;270 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6% (0.4 - 11%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>USA (65)*:</td>
<td>USA (65)*:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25% (20 – 30%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Soon after

Later effect

Data not reported by time since 2nd dose

Soon after

Later effect

Data not reported by time since 3rd dose

65% (62-68%), estimate vs. 2 doses almost identical.

Qatar(105)*:

Only VE relative to primary course (shows booster prevents 50% (47-53%) of symptomatic infections that occur with only a primary course).
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Outcome</th>
<th>2 doses (95% CI in brackets)</th>
<th>3 doses (95% CI in brackets)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Soon after</td>
<td>Later effect</td>
</tr>
<tr>
<td>Symptomatic infection</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onward transmission</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All vaccines</td>
<td>Infection</td>
<td>UKHSA (SIREN study) (77):</td>
<td>UKHSA (SIREN study) (77):</td>
</tr>
<tr>
<td></td>
<td></td>
<td>32% (6-57%)$</td>
<td>62% (41-75%)$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Netherlands: (107)*</td>
<td>Netherlands: (107)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>33% (31-35%)</td>
<td>68% (67-69%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Norway(108)*:</td>
<td>Norway(108)*:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>27% (6 – 49%)‡</td>
<td>45% (26 – 57%)‡</td>
</tr>
<tr>
<td></td>
<td>Symptomatic infection</td>
<td>No Data</td>
<td>No Data</td>
</tr>
</tbody>
</table>

Symptomatic infection

Onward transmission

Infection

All vaccines

UKHSA (SIREN study) (77):
32% (6-57%)$

Netherlands: (107)*
33% (31-35%)

Norway(108)*:
27% (6 – 49%)‡

Spain (109)*:
Only VE relative to primary course (shows booster prevents 51% (50- 52%) of infections that occur with only a primary course).
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Outcome</th>
<th>2 doses (95% CI in brackets)</th>
<th>3 doses (95% CI in brackets)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Soon after</td>
<td>Later effect</td>
<td>Soon after</td>
</tr>
<tr>
<td></td>
<td>Data not reported by time since 2nd dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Onward transmission</strong></td>
<td>Norway(108)*:</td>
<td>% house contacts infected by:</td>
<td>Norway(108)*:</td>
</tr>
<tr>
<td></td>
<td>Unvaccinated 57% (51 - 62%)</td>
<td></td>
<td>Unvaccinated 57% (51 – 62%)</td>
</tr>
<tr>
<td></td>
<td>Partial primary 42% (34 – 49%)</td>
<td></td>
<td>Partial primary 42% (34 – 49%)</td>
</tr>
<tr>
<td></td>
<td>Full primary 51% (47 – 55%)</td>
<td></td>
<td>Full primary 51% (47 – 55%)</td>
</tr>
</tbody>
</table>

* pre-print. Findings not peer reviewed so may change

**additional data available from Hong Kong but appears to exclude those with severe disease. (110) VE 31% (2%-52%) after 2 doses, VE after 3 doses 20-59 years 72% (55-82%), 60+ years 72% (43%-86%)

† Indirect calculation of VE by multiplication of estimates

‡ pre-print with substantial changes in estimates since first posted. Note that study looks at transmission within households, where frequency of contact is higher, often resulting in lower VE estimates than for “per contact” VE estimates (for “leaky vaccines”)

¥ Data points not reported in text. Estimates read from graph, below (Figure 1)

§ Data reported are for those with no prior COVID-19 infection. For those with prior infection these values are 60% (95% CI: 36-75) after 2 doses and 71% (95% CI: 56-82) after 3 doses
In terms of VE against Omicron in comparison to VE against Delta, data from multiple studies (41, 62, 64, 77, 101, 111-113) all suggest reduced VE for 2-dose Pfizer vaccine regimens against symptomatic disease caused by Omicron compared with Delta.

![Figure 1: Pfizer vaccine effectiveness against symptomatic disease by period after 2 doses and after a booster.](77)

**VE against hospitalisation / severe disease**

**VE after receiving a booster dose**

Data from multiple countries (UK, South Africa, USA, Denmark, and Hong Kong) show high vaccine effectiveness (VE) of 89% - 92% against hospitalisation for people aged 18-59+ years >2 weeks after receiving a booster including for those people aged 65 years or older. (102, 114-117) After 10 or more weeks the VE wanes to approximately 75-83%. (114, 115)

**VE after receiving two doses (primary course)**

Data from multiple countries show a vaccine effectiveness of 62% - 70% >2 weeks after receiving the second dose. (77, 116) A US study with mRNA vaccines reported a higher VE of 81%. (117)

After 5-6 months the VE declined to 44% and 57% in the US mRNA study (77) (117), whereas a Danish study reported an increase to 66% after 4 months. (102)

**VE against death**

Qatar: relative VE (compared to the primary course) against any severe, critical, or fatal COVID-19 for a Pfizer booster dose was estimated at 100.0% (95% CI: 71.4-100.0). (105)

Hong Kong: relative VE (compared to the primary course) against mortality for 20-59 years was 83% (-29-98%), 60-69 years 82% (20-96%), 80+ years 66% (-1.3-89%).(110)

**VE of second booster dose (fourth dose)**

Some countries recommend the administration of a second booster dose to elderly populations or individuals at increased risk of severe disease or exposure.

Compared to people vaccinated with 1 booster dose of Pfizer, the marginal VE against infection of a fourth dose peaks at 64% (62-66%) during the third week (118) and provides significantly enhanced protection against severe illness with adjusted rate ratios ranging from 3.4 (2.5-4.7) to 4.3 (2.6-7.1)
after week 4 to 6 weeks. (119) For people aged 60+ year VE peaks after 3-4 weeks at an adjusted rate of 2.1 (119)

A study on efficacy showed the VE 14 to 30 days after the receiving the second booster dose was 52% against PCR confirmed infection, 61% against symptomatic infection, 68% against hospitalisation, and 76% against death compared to one booster dose. (120)

However, marginal VE (relative to the first booster dose) begins to decline four weeks after inoculation, dropping to 29% (18-39%) after nine weeks. (118)

Data from reviews (all vaccines)

A WHO weekly epidemiological report (22 June 2022) included an updated summary of evidence on Omicron, including for vaccine effectiveness. (121)

The WHO notes that results of vaccine effectiveness (VE) studies should be interpreted with caution because estimates vary with the type of vaccine administered and the number of doses and scheduling (sequential administration of different vaccines). (121)

Some key points from the WHO interpretation of results of VE for the Omicron variant include:

- To date, 23 studies from ten countries have assessed the duration of protection of five vaccines against the Omicron variant.
- Findings from these studies show reduced VE of primary vaccine series against the Omicron variant than has been observed for previous variants, for all outcomes (severe disease, symptomatic disease, and infection).
- However, in the majority of studies, VE estimates against the Omicron variant remain higher for severe disease.
- VE estimates against symptomatic disease and infection within the first three months of primary series vaccination tended to be lower than those against severe disease, and VE decreased more substantially over time.

Booster vaccination substantially improves VE for all outcomes, but studies that assess VE of booster vaccination beyond 6 months are needed to evaluate the longer duration of protection.
A more detailed summary of the WHO VE interpretation is below, highlighting results particularly for mRNA vaccines and AstraZeneca.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timing</th>
<th>WHO summary of VE results for Omicron (as at 22 June 2022)</th>
</tr>
</thead>
</table>
| **Severe disease**       | Within first three months of primary series vaccination | mRNA vaccines: seven of 13 (54%) VE estimates were ≥70%  
AstraZeneca: one study reported VE of <70%                                                                 |
|                          | Beyond three months after vaccination             | mRNA vaccines: 13 of 29 (45%) VE estimates for the mRNA vaccines were ≥70% while 20 (69%) were ≥50%  
AstraZeneca: one of the 12 (8%) VE estimates was ≥70% while eight (67%) were ≥50% |
|                          | Between 14 days and three months after receipt of booster | A booster dose improved VE estimates against severe disease in all studies, with only one estimate for Pfizer as the booster dose below 70%. |
|                          | Three to six months post mRNA booster             | 17 of 20 (85%) estimates showed VE ≥70% (an mRNA vaccine was given as the primary series in 13 of the 20 estimates while AstraZeneca-Vaxzevria and Sinovac-CoronaVac were given as the primary series for six and one of the twenty estimates, respectively). |
| **Symptomatic disease**  | Within first three months of primary series vaccination | Only three of 13 (23%) VE estimates for the mRNA vaccines were ≥70%, and seven (54%) were ≥50%; all the three (100%) VE estimates for AstraZeneca were below 50%. |
|                          | Beyond three months after vaccination             | Only 1 of 29 (3%) of the VE estimates were ≥50% (21 estimates evaluated mRNA vaccines, six evaluated AstraZeneca) |
|                          | Between 14 days and three months post booster     | An mRNA booster after completion of a primary series of an mRNA vaccine, AstraZeneca-Vaxzevria, or Sinovac-CoronaVac, improved VE estimates against symptomatic disease, with five of 21 (24%) VE estimates ≥70% and 16 (76%) estimates ≥50%, between 14 days and three months post booster. |
|                          | Three to six months following receipt of an mRNA booster dose | Booster dose protection declined with time since vaccination, with only 2 of 13 (15%) available estimates indicating a VE of ≥50% at three to six months following receipt of an mRNA booster dose. Estimates for a booster dose of AstraZeneca-Vaxzevria (one estimate) and Sinovac-CoronaVac (one estimate) three to six months post vaccination indicated VE of <50%. |
| **Infection**            |                                                   | VE estimates against infection showed a similar pattern as those against symptomatic disease |

SARS-COV-2 VARIANTS OF CONCERN UPDATE 27 of 52
Vaccine response in T-cells & B cells

Section updated: 01 July 2022

A longitudinal study in vaccinated UK health care workers showed that immune response varies based on previous infection and vaccination. (122)

- The study found that different infection histories alongside different timings of vaccination had an impact on immune response against Omicron.

- The study results most relevant to the New Zealand population (vaccinated, and either infection naïve or post-Omicron infection) were that Omicron infection in vaccinated people resulted in some enhancement of neutralising antibody and T-cell response against Omicron, but this enhancement was less than that observed against earlier variants (Alpha and Delta).

- The study cohort contained only vaccinated participants, so the magnitude of immune response to Omicron infection could not be compared to the response in people naïve to any SARS-CoV-2 antigen exposure.

- The study investigators hypothesise that previous order of exposure to SARS-CoV-2 antigens (through vaccination or infection) results in immune imprinting, which affects response to subsequent SARS-CoV-2 exposures.

Neutralising antibody against BA.5

Section updated: 27 July

Neutralisation titres from studies suggest that vaccine-induced neutralising antibody levels against BA.4 and BA.5 are lower than against BA.1 and BA.2 in serum from triple dosed vaccinated individuals, but data remain limited: (123, 124)

- One study (124) compared the neutralization of BA.4/5 28 days after a third dose of AstraZeneca, or Pfizer (BNT162b2) vaccine. (124) The assays showed:
  - For AstraZeneca, neutralization titres for BA.4/5 were reduced 2.1-fold compared to BA.1 and 1.8-fold compared to BA.2.
  - For BNT162b2 neutralization titres were reduced 3.2-fold compared to each of BA.1 and BA.2.

- A pre-print study analysed neutralization of BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.2.13 and BA.4/BA.5 by plasma obtained from those who had had a booster dose (third dose) of CoronaVac four weeks prior. Of the variants tested, the least neutralising antibody was seen against BA.4/BA.5. (123)
Vaccine effectiveness/efficacy in Children

Section updated: 01 July 2022

Vaccination in children is generally split into different age groups. Note: age categories are different between Pfizer-BioNTech and Moderna COVID-19 vaccines:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Approved in NZ*</th>
<th>Age Group</th>
<th>Approved in NZ*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 month - 4 years</td>
<td>No</td>
<td>6 month - 5 years</td>
<td>No</td>
</tr>
<tr>
<td>5-11 years</td>
<td>Yes</td>
<td>6-11 Years</td>
<td>No</td>
</tr>
<tr>
<td>12-17 years</td>
<td>Yes</td>
<td>12-17 years</td>
<td>No</td>
</tr>
</tbody>
</table>

*As of July 2022

Risks to Children under 5 years

- Children are less at risk of becoming severely ill with COVID-19 compared to adults. (125)
  However, according to the CDC:
  - Five times as many children aged 0-4 years were hospitalised during the Omicron wave (Dec, 2021) than from the Delta wave (125)
  - More than 200 deaths of 0–4 year olds have been reported in the US due to COVID-19 since Jan 2020. This accounts for 1.7% of all deaths in this age group (126)
  - Multisystem Inflammation Syndrome (MIS-C) is being seen in children after a SARS-CoV-2 infection with no alternative diagnosis. This is categorised as severe illness, with multisystem organ involvement, fever and inflammation. Although relatively uncommon, MIS-C can present approximately 2-6 weeks following acute infection and generally requires intensive care treatment, with 1-2% of patients dying (126, 127)
  - Long COVID has had impacts on children in this age group with known histories of SARS-CoV-2 infection experiencing symptoms such as fatigue, loss of smell and loss of taste at higher frequencies than children without prior infections (126)

- On the 15 June, an FDA panel endorsed both Moderna and Pfizer COVID-19 vaccines for use in children aged 6 months to 4 years. This was endorsed by the FDA’s Vaccine and Related Biological Products Advisory Committee who voted unanimously to recommend the use of either vaccines which they deemed to be safe and effective in young children against COVID-19. CDC official Sara Oliver says the agency is not favouring one vaccination (Moderna or Pfizer) over the other but that either vaccine is better than none (Washingtonpost).
  - Both vaccines are mRNA based and have the potential to generate antibody levels like those induced in young adults following vaccination.
  - These levels are considered to be protective although this is speculative as the link between antibodies and level of protection is unknown.

- A study (April 2022) suggests that approximately 3 out 4 children in the US have antibodies that show previous infection with SARS-CoV-2, (128) however, the CDC is still recommending vaccination in this group to prevent reinfection
Pfizer COVID-19 Vaccine (Children 6 months- 4 years)

- Pfizer has submitted an amended Emergency use Authorization (EUA) to the FDA for the use of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years. (129) Details of the primary course are:
  - a three-dose series of 3 µg each (compared to two doses of 10 µg in 5-11 and 30 µg doses for all older age groups)
  - intervals of 3 weeks between first and second dose and at least 8 weeks between the second and third dose.
- Overall Pfizer noted that the three doses in 6 month-4 year olds elicited a strong immune response (discussed below with clinical results) and was well tolerated, presenting mild to moderate side effects.
- The data submitted to support the EUA was from an ongoing Phase II/III trial (C4591007). Only data analysed before the 29 April 2022 was included in the EUA, this encompassed safety data from 1,678 children under 5 years old. The trials was a randomised, double blinded trial with 2:1 (placebo control: vaccination). (129)
  - The trial split the participants into two cohorts by age, 6-23 months and 2- 4 years.
  - Patients with a history of past SARS-CoV-2 infection were not excluded from the study.
  - Safety and effectiveness data was collected following the second dose for both age groups. This measured neutralizing geometric mean titres (GMTs) and sero-response rates were assessed against a reference strain.
  - Following analysis of safety and effectiveness data after the first two doses, the protocol was amended to include a third primary dose. After the third dose the trials end points and success criteria were met. (129)
- Trial efficacy:
  - The 2–4 year old cohort had vaccine efficacies of 30% (first dose only) and 40% (second dose). This did not meet that the pre-specified immunobridging success criteria in the 2–4 years cohort.
    - Preliminary analysis of efficacy after a third dose was reported as follows:
      - 6 -23 month cohort: 75.6% (95% CI: -369.1%, 99.6%)
      - 2-4 year old cohort: 82.4% (95% CI: -7.6%, 98.3%)
      - Combined analysis of both age groups: 80.4% (95% CI: 14.1%, 96.7%).
  - Exploratory analysis for immunogenicity against Delta and Omicron variants was performed. This noted similar GMT against Delta (Using B.1.617.2) although significantly lower for Omicron (using BA.1 strain). As this was exploratory, the sensitivity of the assay is unknown. (129)
- Trial Safety:
  - Serious adverse effects (SAE) were reported in similar frequencies in the vaccinated and the placebo groups.
    - 6-23 months cohort: 3.1% reported SAE after vaccination and 2.3% after placebo. The most reported SAE included respiratory illnesses, gastrointestinal or infections, all of which are common within this age group.
2-4 years cohort: 0.7% reported SAE after vaccination and 0.9% after placebo. (129)
  o The risk of SAEs was lower in 6 month-4 year olds what is generally seen in all other age groups (likely due to the lower dose of mRNA). (129)
  o This clinical trial did not indicate any new safety concerns compared to the safety profile of vaccination in older people. (129)
  o Limitations leading to risk in vaccinating 6 month-4 year olds includes uncertainties in:
    ▪ incidence of myocarditis/pericarditis in this age group
    ▪ safety data available in subpopulations (i.e., immunocompromised children or previously infected children). (129)

Modern COVID-19 Vaccine (Children 6 months – 5 years)

Moderna has received FDA authorization for emergency use of COVID-19 vaccine for children 6 months of age and older.(130)

- The Moderna vaccine for 6 month to 5 year olds is a two-dose primary vaccination (25 µg doses, 1 month apart). This is again a lower dose than provided to adults (100 µg/dose). (130)
- The two dose schedule means that the primary course is completed in approximately 1/3 of the time frame required to complete the Pfizer primary course.
- Moderna submitted clinical data from the KidCOVE trial supporting the use of vaccine in 6 month to 5 year olds. This was a randomised, observer blind, placebo control study designed to evaluate the safety, immunogenicity and tolerability of the vaccination. Data from approximately 6,700 children was included in the FDA submission. (130)
- Data was separated by the following age groups:
  o 6 months – 23 months
  o 2 years – under 6 years
- KidCOVE that meet the following objectives:
  o Safety (Primary objective)
    ▪ The vaccine was tolerated by the 6 month to 5 year olds in a consistent way to all other age groups, including adults.
    ▪ Adverse effects were mainly mild or moderate, with more reported following the second dose than the first. Less than 0.2% on participants were reported to have fevers over 40˚C following vaccinations.
    ▪ No new safety concerns were raised
    ▪ No reports of myo/pericarditis, MIS-C or deaths.
  o Immunogenicity (Primary objective)
    ▪ Interim results, released on 23 March 2022, showed a robust neutralising antibody results in children aged 6 months - 5 year old which was comparable the response in young adults (despite the lower dose vaccine).
  o Efficacy (Secondary objective)
- Vaccine efficacy was 51% and 37% for 6-23 month and 2-5 year olds respectively.
- This was considered as satisfactory to the studies primary objective and comparable to adult efficacy to Omicron.

Children aged 5-11 years

- Since January 2022, children aged 5 - 11 years have been eligible for two doses of Pfizer, with 8 week intervals between doses in New Zealand. Children are not currently eligible for third doses, unless severely immunocompromised.
- Currently, only the Paediatric dose of Pfizer is offered to this age group in New Zealand.

Pfizer COVID-19 Vaccine (Children 5-11 years)

- The primary series for two dose this age group is 10 µg per vaccination (compared to three doses of 3 µg in 6month-4 years and two doses of 30 µg doses for 12 years and older age groups)
- Prevention of infection from Omicron after two doses of Pfizer in children aged 5-11 ranges from 31% to 68%.(131, 132) Multiple studies have evidence of a significant reduction in the efficacy of the Pfizer vaccine in 5 to 11 years in preventing infection against Omicron compared to the 90.7% reported before the emergence of Omicron during a high Delta prevalence.(133)
- A preprint study has shown evidence that the effectiveness of the Pfizer vaccine may wane more rapidly in 5–11 year olds than other age groups.(134)
- The study reported a 65% vaccine efficacy against infection within 14 days of vaccination, but this declined rapidly to just 12% within 28-34 days.(134) Adolescents are afforded a greater level of protection against infection from Omicron by the Pfizer vaccine. (131)
- One study found a vaccine efficacy against infection from Omicron for 12-15 year olds remains >59% 150 days after vaccination. (131) Similarly, it was found that vaccine efficacy against infection in 12-17 year olds was 66% within 14 days of vaccination but only decreased to 56% within 28-34 days.(134)

Omicron: immune evasion

Section updated: 16 May 2022

Neutralising assays

- Neutralisation studies provided initial data predicting lower vaccine effectiveness against Omicron than for previous variants.(135-140) These data have now been superseded by effectiveness data.
- BA.2 does not appear to have a greater capacity for immune evasion by antibody neutralisation than BA.1. (141-143)
Cell-mediated responses

While data remain preliminary, an increasing number of studies indicate that vaccination provides a durable T-cell response to Omicron infection.(135, 144-147)

Immunopathological characteristics

Omicron breakthrough patients had a more robust IFN-y response (critical for viral clearance) and lower concentration of proinflammatory cytokines at the acute phase of infection. They also had lower frequency of immature neutrophils indicating milder inflammatory response.(56)

Reinfection

Reinfection after previous infection with a “pre-Omicron” variant

- Several studies have estimated the effectiveness of previous infection with a pre-Omicron variant (e.g. Delta) against reinfection with Omicron. Effectiveness estimates range from 15% to 61.9% (6, 77, 148, 149), but it is often unclear in studies when the previous infection occurred relative to the study period, making it difficult whether this variability is due to waning of effect. Effectiveness against hospitalisation/death was 87.8%. (148)

Reinfection after previous Omicron infection

- Infection with previous Omicron variants provides protection against subsequent Omicron Infection. Previous Omicron infections is estimated to provide between 76% and 94% protection against symptomatic BA.4/5 infection (time period not reported, but likely within 3 to 5 months since previous infection). (5, 6)
  o A study in Qatar (conducted approximately 5 months after first Omicron wave (150)) estimated the effectiveness of a previous Omicron infection against symptomatic BA.4/BA.5 reinfection was 76.1% (95% CI: 54.9-87.3%), and against any BA.4/BA.5 reinfection was 79.7% (95% CI: 74.3-83.9%).(6)
  o A Danish study (conducted approximately 3 months after first Omicron wave (150)) estimated the effectiveness of a previous Omicron infection on BA.5 infection among triple-vaccinated individuals.(5) Prior omicron infection was highly protective against BA.5 (94%, 95%CI 92-95).(5)

Omicron: effectiveness of therapeutics

Section updated: 30 June 2022

Therapeutic use for treatment of COVID-19

- Most people can safely manage their own COVID-19 symptoms at home. However, for people with increased risk factors or comorbidities, different therapeutic options may provide improved outcomes for the patient.
- The Ministry of Health has an overview about COVID-19 therapeutics and advice for healthcare professionals websites.
- Therapeutic options currently include antiviral medications (paxlovid, remdesivir, molnupiravir), anti-SARS-CoV-2 monoclonal antibodies (evusheld, sotrovimab), immunomodulators (bara tocilizumab) and anti-inflammatory drugs (dexamethasone, budesonide) available as EUA for
COVID-19 management. The utility, effectiveness and need for each of these options is different between individuals, and criteria for each is specific, based on disease severity and individual risk factors.

- The emergence of new variants produces challenges to the therapeutics as adaptive mutations can completely alter the viral genome and pathogenic potential. New variants that become VOC are often associated with increased virulence, pathogenicity and transmissibility which may help them evade the immune response and have decreased effectiveness to current therapeutics. (151, 152)

**Therapeutics in relation to BA.4 and BA.5**

- Many monoclonal antibodies showed reduced efficacy against Omicron variants relative to Delta. (153)

- Additionally, although many of the newer Omicron subvariants are derived from BA.2, there are significant mutations to the spike. (152) It has been established that this reduces the sensitivity to vaccine-induced neutralising antibodies. (154, 155) As a result, it becomes likely that these variants will also have reduced sensitivity to therapeutic monoclonal antibodies. (152)

- Evusheld is a long-acting antibody combination (tixagevimab and cilgavimab) derived from the B cells of individuals previously infected by SARS-CoV-2. There are conflicting data supporting its effectiveness against BA.4/5.
  - A press release by AstraZeneca (who manufacture the drug) reports data from multiple sources showing neutralising against BA.2, the global dominant variant currently, and all other variants tested to date (May, 2022). One study, (124) based at the University of Oxford, has in vitro data showing that Evusheld retains neutralisation efficacy against Omicron variants including BA.4 and BA.5.
  - In contrast, another study reported that BA.4/5 showed an increased resistance to Evusheld compared to BA.2 variant. This was estimated at an increase of approximately 20-fold times resistant. (152)

- A preprint study suggested that among the therapeutic antibodies authorized for clinical use, only bebtelovimab (LY-COV1404) retains full potency against both BA.2.12.1 and BA.4 and BA.5. (156)
Omicron: Detection

PCR

Section updated: 16 May 2022

Most observational studies have relied on SGTF as a proxy for Omicron, which identify BA.1 but not BA.2. Therefore, caution is required when interpreting comparative analyses which use S-gene target results as the only determinant of Omicron and Delta.

- BA.2 lineage generally does not have the spike deletion at 69-70 that causes S-gene target failure (SGTF).(77) Nicknamed “stealth” version of Omicron as it cannot be detected using PCR tests that detect SGTF, such as Thermo Fisher’s TaqPath. (link)
- This has implications on using PCR tests that detect SGTF as a proxy for rapidly detecting Omicron cases. It should be noted that as at 30 March 2022, the UKHSA reported that 0.16% of BA.2 samples sequenced had the deletion at position 69-70.(24)

Rapid Antigen Tests (RATs)

Section updated: 22 July 2022

PCR testing remains the gold standard for SARS-CoV-2 diagnostics, however the longer turnaround time and requirement for laboratory settings is unsuitable for large scale testing. Rapid antigen tests (RAT) are now the primary diagnostic tool in New Zealand, due to their fast turnaround time, general lack of equipment and ability to be self-administered from home.

The performance of a RAT is generally measured against two outputs, sensitivity and specificity. These are defined as the following:

- sensitivity: a measure of how well the test identifies true positives (i.e., result is identified by test as positive and are positive)
- specificity: a measure of how well the test identifies true negatives (i.e., result is identified by test as negative and are negative).

The list of approved point of care test (POCT) devices in New Zealand can be found here. These were approved based on clinical performance data that meets the following thresholds:

- Overall ≥80% sensitivity and >98% specificity (recommended by WHO, ECDC, TGA, and European Commission MDCG) compared to the gold standard RT PCR
  Or
- ≥90% sensitivity for Ct values <25

Detection of Omicron by Rapid Antigen Tests

Accurate diagnostic tools are essential in controlling the pandemic, however reliably detecting emerging variants provides challenges. Many of the RATs were developed prior to the emergence of new variants and are based on the reference sequence of the 2019 Wuhan-hu-1 virus. (157) Although nucleocapsid proteins are the most common antigen detected by RAT devices, (157) the spike protein receptor is also a common target for detection.(158) BA.1, when compared to Wuhan-hu-1 virus, has four mutations in the nucleocapsid protein for BA.1, with BA.2 having an additional mutation.(157) The spike region contains even more mutational differences between the initial SARS-CoV-2 virus and
many new variants. Diagnostic tools targeting the Wuhan-hu-1 virus potentially face challenges in detecting later variants because of mutations in the antigen target.

The FDA has cautioned that RAT devices may have reduced sensitivity to Omicron since its emergence towards the end of 2021. However, it should be noted that it is challenging to compare across studies given that initial data on RAT performances were collected in clinical settings by healthcare workers, and as such real-world data may not match the reported performances. Sensitivity is also highly variable between different RATs and is strongly correlated with viral load and symptomatology.

For many RATs, the sensitivity was above 80% when initially tested in clinical settings. A study in June 2022, reported sensitivity to Omicron is likely to be closer to 63% in one device (this device is not approved for use in New Zealand) while a pre-print (July 2022) assessed the sensitivity of three different devices (approved for use in New Zealand) and reported this may be as low as 27.5% in self-testing asymptomatic people. Another study (Feb 2022) reported that the limit of detection for Omicron (BA.1.1.529) was 10-fold higher than detection for Delta. However, the authors note that the results of the in vitro test utilised was not reflected after testing cultured (expanded) virus. Additionally, the issues around comparability across studies, settings and devices apply across these publications.

All RATs available in New Zealand have been screened for acceptable performance. In light of the number of mutations in the Spike protein that occurs in Omicron, RATs which target other less mutated antigens such as the ‘N’ or ‘E’ proteins are more likely to maintain high performance of detecting Omicron.

There is no strong evidence that there has been a significant decline in the performance of RATs in detecting newer variants of SARS-CoV-2. However, test performance will require ongoing review as new variants arise.

New signals

Section updated: 22 July 2022

- The risk of clinically significant emerging variants is considered to be high, according to the WHO. The WHO has expressed concern that during recent months, some countries have significantly reduced SARS-CoV-2 testing. They caution that unless robust surveillance systems are retained, countries may lose the ability to accurately interpret epidemiological trends, implement the appropriate measures necessary to reduce transmission and monitor and assess the evolution of the virus.

BA.2.75

- BA.2.75 is a novel omicron variant of the BA.2 lineage which has nine new mutations in the spike protein receptors distinguishing it from BA.2. This variant emerged in India in early May with cases reported in over 17 countries by mid-July 2022. The first two community cases within New Zealand were reported on the 19 July 2022. The World Health Organisation (WHO) has classified BA.2.75 as a variant-of-concern lineage under monitoring on the 7 July 2022. Key opinion leaders state that early reports suggest BA.2.75 is more transmissible than other BA.2 subvariants and that in India this variant is competing (as of mid/late-July) with the most prevalent strain, BA.5.

- One study has found that BA.4/BA.5 are more resistant to therapeutic monoclonal antibody treatments than BA.2. As BA.2.75 has a greater number of spike mutations than BA.4/BA.5, there is potential for BA.2.75 to have a greater reduced sensitivity to monoclonal antibodies.
than these other variants. It is unknown whether this variant will be able to cause serious illness, as reports on hospitalisation and mortality rates have not yet been recorded.

**BA.5.2.1**
- A new subvariant of the Omicron BA.5 lineage detected in China on the 8 July 2022. (11) The first confirmed case of BA5.2.1 was detected in Shanghai with cases since confirmed across multiple provinces. (11) The original case has been linked to travel from Uganda, there is limited scientific evidence around the properties of this variant, such as the transmission potential and disease severity.

**BA.2.12 and BA.2.12.1**
- New York State Department of Health announced the emergence of two Omicron subvariants in New York State, BA.2.12 and BA.2.12.1 on 13 April 2022, both sub-lineages of BA.2.(163)
  - Estimated to have a 23% – 27% growth advantage above BA.2. New York Department of Health reported no evidence of increased disease severity by these subvariants.(163)
  - The CDC estimated 36.5% (95% PI 28.9-44.9%) of COVID-19 cases in the United States to be BA.2.12.1 as of 30 April 2022.
- BA.2.12.1 has a substitution mutation at the L452 location (L452Q). This is similar to BA.4/B.5 which have L452R.(164)
  - A mutation to L452 location has arisen independently in other variants including Delta, Epsilon, Kappa. This mutation is linked to immune evasion and cell binding, making it a mutation of interest in new variants.(165)
- BA.2.12.1 has been shown to have increased immune evasion abilities compared to BA.2.(165)
  - BA.2.12.1 has strong neutralising evasion against plasma taken from people with previous BA.1 infection (both 3-dose vaccinated and unvaccinated).(165).
- A preprint study that used sera from both vaccinated and boosted individuals, found BA.2.12.1 to be modestly more (1.8-fold) resistant to neutralization than BA.2.(156)
- Cell culture experiments showed increased replication efficiency of BA.2.12.1 in human alveolar epithelial cells than BA.2, producing viral titres that were 61-fold higher than cells infected with BA.2. (166)

**Delta Overview**

*Section updated: 20 May 2022*

- UKHSA no longer classifies Delta as a Variant of Concern, however the WHO does.
- A study has raised concerns that Delta could continue to pose a threat. ([link](#))
  - Variants tend to disappear when dominated by the next variant.
  - Wastewater surveillance in Israel found that even at the height of the Omicron wave, the Delta variant was still detected at low levels.(167)
  - Modelling suggests that Omicron levels may decrease until it is eliminated, while the Delta variant could maintain its ‘cryptic circulation’, possibly resulting in the re-emergence of a Delta wave or generation of a new variant.
### Glossary of Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>The AstraZeneca vaccine</td>
<td>AZD1222 or ChAdOx1</td>
</tr>
<tr>
<td>The Pfizer/BioNTech vaccine</td>
<td>Comirnaty/BNT162b2</td>
</tr>
<tr>
<td>Global Initiative on Sharing Avian Influenza Data (GISAID)</td>
<td>This is a consortium that promotes and provides open access to SARS-CoV-2 genomic sequence data. Its original purpose was for sharing data on avian (bird) flu.</td>
</tr>
<tr>
<td>Immune escape</td>
<td>The ability of the virus to evade our body’s immune response. See also Immune response.</td>
</tr>
<tr>
<td>Immune response</td>
<td>The response of our immune system to an infection. It includes development of specific antibodies to the virus and also cell-mediated responses (triggered by T cells).</td>
</tr>
<tr>
<td>Mutation</td>
<td>Small change made to the pattern of nucleotides that make up the virus. These occur as the virus spreads and replicates. Most do not confer a benefit to the virus.</td>
</tr>
<tr>
<td>Naming mutations</td>
<td>Mutation nomenclature (i.e., how they are named), describes what occurred at a specific location of the genome. For example, the ‘E484K’ mutation means that at the position 484, the amino acid changed from glutamic acid (E) to lysine (K). When a deletion occurs, the location is provided (e.g., deletion 144).</td>
</tr>
<tr>
<td>N-terminal domain</td>
<td>Part of the spike protein of the SARS-CoV-2 virus.</td>
</tr>
<tr>
<td>R&lt;sub&gt;0&lt;/sub&gt;, Reproductive number</td>
<td>The reproductive number R&lt;sub&gt;0&lt;/sub&gt; (R-naught), is a measure of how contagious a disease is. It is the average number of people who would catch a disease from one infected individual when there are no control measures in place, e.g., vaccination, lockdowns.</td>
</tr>
<tr>
<td>R&lt;sub&gt;eff&lt;/sub&gt;, Effective reproductive number</td>
<td>The ‘effective R’ (R&lt;sub&gt;eff&lt;/sub&gt;) is the R observed when control measures are in place. R&lt;sub&gt;eff&lt;/sub&gt; can therefore change depending on the control measures currently enacted in a particular population. In general, whenever R is less than 1, i.e., an infected person goes on to infect less than one person on average, then the prevalence of the disease would be expected to decrease.</td>
</tr>
<tr>
<td>Secondary attack rate</td>
<td>The probability that an infection occurs among persons within a reasonable incubation period after known contact with an infectious person in household or other close-contact environments.</td>
</tr>
<tr>
<td><strong>• Serial interval</strong></td>
<td>The time from symptom onset of a case to symptom onset in their identified contacts.</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>• SGTF / SGTP</strong></td>
<td>“The Omicron genome (lineage BA.1) contains the spike deletion at position 69/70 which is associated with S-gene target failure (SGTF) in some widely used PCR tests. Such PCR tests evaluate the presence of 3 SARS-CoV-2 genes: Spike (S), nucleocapsid (N) and ORF1ab. SGTF is defined as a PCR test where the N and ORF1ab genes are detected (with Ct values less than or equal to 30) but the S-gene is not. SGTF patterns can be used to assess the spread of Omicron lineage BA.1. The Omicron lineage BA.2, VOC-22JAN-01, does not generally contain the spike gene deletion and is S-gene target positive (SGTP).” (24)</td>
</tr>
<tr>
<td><strong>• Variant</strong></td>
<td>Viruses with mutations are referred to as variants of the original virus. New variants of SARS-CoV-2 have been emerging as the virus has spread and evolved.</td>
</tr>
</tbody>
</table>
| **• Variant of Concern (VOC)** | **WHO definition:** A SARS-CoV-2 variant that meets the definition of a VOI (see below) and, through a comparative assessment, has been demonstrated to be associated with one or more of the following changes at a degree of global public health significance:  
  - Increase in transmissibility or detrimental change in COVID-19 epidemiology; OR  
  - Increase in virulence or change in clinical disease presentation; OR  
  - Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics. |
| **• Variant of Interest (VOI)** | **WHO definition:** A SARS-CoV-2 variant:  
  - with genetic changes that are predicted or known to affect virus characteristics such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape; AND  
  - Identified to cause significant community transmission or multiple COVID-19 clusters, in multiple countries with increasing relative prevalence alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health. |
| **• Variant under Investigation (VUI)** | **UKHSA definition:** SARS-CoV-2 variants, if considered to have concerning epidemiological, immunological or pathogenic properties, are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following a risk assessment with the relevant expert committee, they may be designated Variant of Concern (VOC). |
Abbreviations

- **CDC**: Centers for Disease Control and Prevention
- ** Ct**: Cycle Threshold
- ** E**: Glutamic Acid
- ** GISAID**: Global Initiative on Sharing Avian Influenza Data
- ** ICU**: Intensive Care Unit
- ** IPC**: Infection Prevention and Control
- ** L**: Lysine
- ** mRNA**: messenger RNA
- ** N**: Nucleocapsid (Protein)
- ** NPI**: Non-pharmaceutical intervention
- ** PCR**: Polymerase Chain Reaction
- ** RBD**: Receptor binding domain (of the virus spike protein)
- ** RAT**: Rapid Antigen Test
- ** R_{eff}**: ‘Effective R’, the effective reproductive number

** R_{0}**: ‘R-naught’, the baseline reproductive number

** RNA**: Ribonucleic Acid

** S**: Spike (Protein)
  - ** UKHSA**: UK Health Security Agency

** UAI**: Upper Airway Infection

** VE**: Vaccine effectiveness

** VTG**: Variant Technical Group

** WHO**: World Health Organisation
# Useful Links

<table>
<thead>
<tr>
<th>US CDC – SARS CoV-2 variant classifications and definitions</th>
<th><a href="#">CDC classification of variants</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Outbreak Info</td>
<td><a href="#">Outbreak Info</a></td>
</tr>
<tr>
<td>WHO - Tracking SARS-CoV-2 variants</td>
<td><a href="#">WHO Variant Tracking</a></td>
</tr>
<tr>
<td>UK Health Security Agency Technical Briefings (from October 2021 onwards)</td>
<td><a href="#">Investigation of SARS-CoV-2 variants: technical briefings</a></td>
</tr>
<tr>
<td>Public Health England Technical Briefings</td>
<td><a href="#">Investigation of SARS-CoV-2 variants: technical briefings</a></td>
</tr>
</tbody>
</table>
References

10. Topol E. In: @EricTopol, editor.: twitter; 2022.


65. Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans. 2022. 2022.01.15.22269360]. Available from: [http://medrxiv.org/content/early/2022/01/18/2022.01.15.22269360.abstract](http://medrxiv.org/content/early/2022/01/18/2022.01.15.22269360.abstract).


75. Houhamdi L, Gautret P, Hoang VT, Fournier P-E, Colson P, Raoult D. Characteristics of the first 1,119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021. Journal of Medical Virology. 2022;n/a(n/a).


78. Torjesen I. Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children. BMJ. 2022;376:e110.


125. Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022 [Internet]. 2022.
Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention; 2022 17
June 2022.
Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Network
129. Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee
Meeting June 15, 2022 FDA Briefing Document EUA amendment request for Pfizer-BioNTech COVID-19
Vaccine for use in children 6 months through 4 years of age. 2022. Available from:
https://www.fda.gov/media/159195/download.
Children 6 Months of Age and Older. 2022.
131. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-Dose BNT162b2
(Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years
and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal
2022;386(20):1899-909.
134. Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the
BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the
Omicron Variant. Feb 28 2022. Available from:
https://www.medrxiv.org/content/10.1101/2021.12.27.21268416.
Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients. medRxiv; 2021. Available from:
https://doi.org/10.1101/2021.12.27.21268459.
heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2
variants Delta and Omicron: the Dominican Republic Experience. medRxiv, 2021. Available from:
CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies. bioRxiv; 2021.
Strong Protection Against SARS-CoV-2 Omicron Variant in Cancer Patients. medRxiv; 2021. Available from:
140. Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. The significant immune escape of pseudotyped SARS-
2022. Available from:
SARS-CoV-2 Omicron BA.1 and BA.2 Variants. 2022. 02.06.22270533]. Available from:
http://medrxiv.org/content/early/2022/02/07/2022.02.06.22270533.abstract.


